Sunscreen TEAs Should Model Applications For Chronic-Use Cutaneous Drugs – FDA
This article was originally published in The Tan Sheet
Executive Summary
TEAs for UV filters should provide FDA with clinical safety data used to support approval of chronic-use cutaneous drugs and nonclinical testing should focus on potential long-term adverse effects, according to draft guidance required under the Sunscreen Innovation Act. FDA particularly is interested in comments about final formulation safety testing it anticipates requiring under specified monograph conditions.
You may also be interested in...
Manufacturers Argue FDA Sunscreen Reviews Keep Outside Science In Shade
FDA officials and the Public Access to Sunscreen Coalition will meet Nov. 1 in effort to find common ground between FDA and outside scientists on standards for testing requirements of new sunscreens under one of four draft guidances the agency is scheduled to finalize by the end of the year.
Manufacturers Argue FDA Sunscreen Reviews Keep Outside Science In Shade
FDA officials and the Public Access to Sunscreen Coalition will meet Nov. 1 in effort to find common ground between FDA and outside scientists on standards for testing requirements of new sunscreens under one of four draft guidances the agency is scheduled to finalize by the end of the year.
Sunscreen Guidances Underscore FDA Standards Aren’t Changing
CDER has published guidances, required by the 2014 Sunscreen Innovation Act, on FDA’s process for advisory committees to consider firms’ sunscreen ingredient proposals and on withdrawing pending proposals being considered by the agency.